Wells Fargo & Company MN grew its stake in LeMaitre Vascular Inc (NASDAQ:LMAT) by 17.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 134,482 shares of the medical instruments supplier’s stock after purchasing an additional 20,296 shares during the period. Wells Fargo & Company MN owned approximately 0.70% of LeMaitre Vascular worth $5,032,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA grew its holdings in LeMaitre Vascular by 11,612.5% during the second quarter. BNP Paribas Arbitrage SA now owns 3,748 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 3,716 shares during the period. Teachers Retirement System of The State of Kentucky acquired a new position in LeMaitre Vascular during the second quarter worth $137,000. Victory Capital Management Inc. grew its holdings in LeMaitre Vascular by 181.2% during the third quarter. Victory Capital Management Inc. now owns 4,139 shares of the medical instruments supplier’s stock worth $155,000 after acquiring an additional 2,667 shares during the period. Royce & Associates LP acquired a new position in LeMaitre Vascular during the second quarter worth $156,000. Finally, Royal Bank of Canada grew its holdings in LeMaitre Vascular by 856.5% during the second quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 4,505 shares during the period. 69.24% of the stock is currently owned by institutional investors and hedge funds.
Shares of LeMaitre Vascular Inc (NASDAQ:LMAT) opened at $30.65 on Friday. The firm has a market capitalization of $583.05, a price-to-earnings ratio of 39.29, a price-to-earnings-growth ratio of 2.39 and a beta of 0.54. LeMaitre Vascular Inc has a twelve month low of $19.82 and a twelve month high of $39.88.
LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.05. The company had revenue of $24.80 million for the quarter, compared to analyst estimates of $25.49 million. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. LeMaitre Vascular’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.17 earnings per share. research analysts anticipate that LeMaitre Vascular Inc will post 0.84 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, December 7th. Shareholders of record on Wednesday, November 22nd were issued a $0.055 dividend. This represents a $0.22 annualized dividend and a yield of 0.72%. The ex-dividend date of this dividend was Tuesday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 28.21%.
In other LeMaitre Vascular news, insider David B. Roberts sold 4,123 shares of the company’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $32.14, for a total value of $132,513.22. Following the sale, the insider now owns 24,482 shares of the company’s stock, valued at $786,851.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 23.70% of the stock is currently owned by corporate insiders.
A number of brokerages recently weighed in on LMAT. Canaccord Genuity reaffirmed a “hold” rating and set a $30.00 price objective on shares of LeMaitre Vascular in a report on Monday, October 9th. Zacks Investment Research lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Thursday, September 28th. Benchmark lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, October 27th. First Analysis lowered LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 price objective on the stock. in a report on Friday, October 27th. Finally, BidaskClub lowered LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Saturday, December 2nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. LeMaitre Vascular has a consensus rating of “Hold” and an average price target of $32.20.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.